Beyond Efficacy: The Battle for MS Preference

Why is MS competition moving beyond efficacy?

Multiple sclerosis has long been a market defined by efficacy: relapse reduction, MRI outcomes and the ability to slow disease activity. That remains essential. But as high-efficacy therapies become more established, treatment preference is being shaped by a broader question: which therapy best fits how neurologists, MS centers and treatment networks want to deliver care^[1]?

For much of the modern MS era, therapies competed through a familiar set of attributes: disease activity, safety, dosing frequency and specialist confidence. Infusion centers, hospital outpatient departments and specialist MS clinics were central to administering and monitoring many high-efficacy therapies. Today, treatment choice is more complex.

Neurologists can consider infusion-based anti-CD20 medicines, self-administered anti-CD20 options, oral disease-modifying therapies, immune-reconstitution approaches and emerging BTK inhibitors. The decision is no longer solely about whether a medicine suppresses disease activity^[2]. It is also about how treatment fits a patient's clinical course, a provider's workflow and a health system's ability to deliver ongoing care.

What decides treatment preference in multiple sclerosis?

Six terms, taken together, describe the care model a therapy asks a network to run. Select a term to see why it shapes preference.

The next MS winner may not be the medicine with the most novel mechanism. It may be the therapy that best fits the treatment setting in which neurologists want to deliver high-efficacy care.

How has anti-CD20 therapy changed the MS baseline?

Anti-CD20 therapies have become central to high-efficacy MS treatment. But they are not all competing through the same care model^[1]. Three products illustrate three different demands on a treatment network.

1. 01

   Ocrevus made infusion capacity part of the equation

   Roche and Genentech's Ocrevus helped establish the role of B-cell depletion across relapsing forms of MS and primary progressive MS. Its infusion-based model has made infusion capacity, hospital workflows, safety monitoring and specialist-center infrastructure part of the treatment equation.^[3]

2. 02

   Kesimpta offered a route out of the infusion center

   Novartis's Kesimpta presents a self-administered subcutaneous anti-CD20 therapy. It gives clinicians and patients an option that can reduce dependence on infusion-center capacity while retaining a high-efficacy treatment framing.^[4]

3. 03

   Briumvi turned throughput into positioning

   TG Therapeutics' Briumvi adds another anti-CD20 option, with an infusion profile that can affect site throughput and account-level positioning.^[5]

In a crowded anti-CD20 market, operational questions such as infusion duration, scheduling, monitoring requirements and care-team workload can become commercially meaningful.

How are Roche and Novartis building different preference propositions?

Roche and Novartis illustrate the shift particularly clearly. Roche's position has historically been tied to Ocrevus and its broad MS franchise. Now fenebrutinib, an investigational oral BTK inhibitor, could give Roche a potential route into a different treatment format and a progression-focused clinical conversation^[6].

In February 2026, Roche stated that fenebrutinib was the first investigational medicine in more than a decade to reduce disability progression in primary progressive MS. For Roche, the strategic opportunity is not merely to add a new asset. It may be to give neurologists options across infusion-based B-cell depletion and potential oral progression-focused therapy^[3][6].

Novartis already has a contrasting anti-CD20 model in Kesimpta. If it adds an oral BTK option to its MS portfolio, it could potentially address several points in the treatment journey, from early high-efficacy treatment to patients for whom oral administration or progression-related evidence becomes more relevant. The strategic lesson is that product portfolios may increasingly compete as choice architectures, rather than as individual brands.

What happens when the battleground moves beyond relapse control?

For years, relapse reduction has been the central clinical and commercial metric in MS. But disease progression, especially progression independent of relapse activity, has remained difficult to address. That is why BTK inhibitors are attracting attention: their potential relevance lies in the possibility of influencing both peripheral and central nervous system immune activity.

Sanofi's Cenrifki (tolebrutinib) illustrates the importance of this shift. In June 2026, the European Commission approved Cenrifki for non-relapsing secondary progressive MS, positioning it as the first disability-targeting therapy for this population^[7]. For Sanofi, the opportunity is not simply to compete in the broad relapsing-MS market. It is to create relevance in a patient segment where the clinical and commercial narrative is about disability progression rather than relapse frequency.

The broader question is whether progression-focused evidence will reset what neurologists expect from new MS therapies. If it does, existing high-efficacy brands may need to demonstrate not only relapse control, but also a credible long-term role in preventing disability accumulation.

Who actually decides which MS therapy is used?

Treatment preference is not decided in a vacuum. It is shaped by the institutions and professionals responsible for delivering care, from academic MS centers through infusion providers to specialty pharmacies and payers.

Academic MS centers lead adoption of complex, high-efficacy and emerging therapies and influence treatment standards, while community neurologists determine how far high-efficacy therapy can scale beyond specialist centers. Infusion centers affect scheduling, throughput, staffing and treatment convenience for infused products, and hospital outpatient departments influence protocol adoption, formulary practice and safety-monitoring processes.

Specialty pharmacies coordinate dispensing, adherence and support for self-administered and oral therapies. Integrated neurology networks shape referral, diagnostic, monitoring and follow-up models. Payers and health systems influence product choice through site-of-care, formulary and utilization-management decisions.

An infusion-based therapy may be clinically well understood but operationally demanding. A self-administered therapy may improve convenience but require different adherence and support infrastructure. An oral medicine may reduce administration burden but create a distinct monitoring and safety-management profile. This means commercial success increasingly depends on understanding where each therapy fits at the account level.

What are the leading MS companies signaling?

In the US, companies must address not only specialist confidence but also account workflow, site-of-care economics, pharmacy coordination and treatment initiation^[8]. In the EU, hospital-based care, national treatment guidelines, country-specific reimbursement and specialist-center capacity play a more prominent role.

Sanofi's EU approval of Cenrifki demonstrates how regulatory progress can create a distinct regional opportunity in progressive disease^[7]. Meanwhile, Roche's fenebrutinib data could shape a different conversation around progressive MS if it translates into regulatory and clinical adoption^[9].

The message is not that route of administration will replace efficacy. It is that, once therapies meet a high-efficacy threshold, treatment delivery may become the next important source of preference.

What should an emerging MS company do differently?

For an emerging MS company, an effective therapy may not be enough. It needs a credible role in the treatment ecosystem. The practical strategic question is which treatment setting is most likely to choose this therapy, and why.

For smaller companies, the opportunity may be to solve a practical treatment problem that an established franchise does not: reducing monitoring burden, improving convenience, addressing progression or creating a viable option after anti-CD20 treatment.

What is still unresolved in the MS market?

Public clinical data and regulatory milestones show a market moving beyond a single definition of high-efficacy therapy. But they do not fully explain how neurologists will make treatment choices once several clinically credible options are available.

Those questions sit with the professionals shaping MS care: neurologists, MS-center leaders, infusion providers, specialty pharmacists, hospital formulary stakeholders, former industry leaders and care-network administrators.

The next MS winner may not be the therapy with the most differentiated mechanism. It may be the one that best fits how neurologists and treatment networks want to deliver high-efficacy care.